Certara Inc (CERT) - News Archive

Certara Completes Acquisition of ChemAxon: What It Means for the Company and Its InvestorsIn a move set to redefine its position in the life sciences industry, Certara Inc. (NASDAQ: CERT), a recognized leader in scienti...

In the ever-evolving field of oncology, the quest for innovative therapies that can effectively target cancer has led to exciting collaborations aimed at optimizing drug development. A notable recent partnership is betw...

Certara Broadens Drug Discovery Software Portfolio with ChemAxon AcquisitionIn a strategic move to enhance its drug discovery software offerings, Certara Inc. has announced its definitive agreement to acquire ChemAxon,...

Certara Unveils Next Generation AI Writing Software and Reports Revenue Increase in Q1 2024Certara, a leading provider of drug development and regulatory science software, announced the launch of its advanced CoAuthor r...

In a recent press release, Certara Inc, a renowned global leader in biosimulation, announced its acquisition of Applied BioMath, marking a significant expansion of its biosimulation portfolio. This strategic move aims t...

Increasing Efficiency and Performance in Drug Formulation and Development: Certara s Simcyp Biopharmaceutics SoftwareCertara Inc, a leading drug research and development company, has introduced the Simcyp Biopharmaceuti...